Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Novartis AG — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $19 (market cap $8.59B), while Novartis AG trades at $152.63 (market cap $295.37B). The key difference: Novartis AG is far larger — about 34.4× Norwegian Cruise Line Holdings Ltd's market cap, and Novartis AG pays a 3.07% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| NCLH | NVS | |
|---|---|---|
Market Cap | $8.59B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $26.94 | $168.62 |
52-Week Low | $14.79 | $119.31 |
Enterprise Value | $23.40B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NCLH trades at $19.09, up 2.91% today, with a bearish technical signal but recent earnings beats. The company reported Q2 2026 EPS of $0.48, exceeding the $0.4115 estimate, and revenue growth has improved from $4.8B in 2022 to $9.83B in 2025. However, net income margin declined to 4.3% in 2025 from 9.6% in 2024, and high debt levels remain a concern with total liabilities of $18.54B against equity of $1.43B.
The outlook is mixed: analyst consensus is a Buy with a $20.73 price target, but risks include volatile fuel costs, macroeconomic pressures on travel demand, and execution of turnaround plans. The stock offers value with a P/E of 11.33, yet investor sentiment is cautious due to recent guidance cuts and bearish technical indicators.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
